藏药治疗糖脂代谢性疾病的研究进展  

Research progress on the treatment of metabolic diseases of sugar and lipids with Tibetan medicines

作　　者：杨蓁蓁 甄罗曦 周修腾[2] 罗朵生[1] YANG Zhenzhen;ZHEN Luoxi;ZHOU Xiuteng;LUO Duosheng(Metabolic Diseases Research Center of Integrated Traditional Chinese and Western Medicine in Guangdong Province,Guangdong Pharmaceutical University,Guangzhou 510006,China;National Resource Center for Chinese Materia Medica,China Academy of Chinese Medical Sciences/State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs,Beijing 100700,China)

机构地区：[1]广东省代谢病中西医结合研究中心,广东药科大学,广州510006 [2]中国中医科学院,中药资源中心,道地药材品质保障与资源持续利用全国重点实验室,北京100700

出　　处：《西北药学杂志》2025年第2期240-252,共13页Northwest Pharmaceutical Journal

基　　金：中国中医科学院科技创新工程项目(编号:CI2021B014)。

摘　　要：目的通过归纳总结藏药治疗糖脂代谢性疾病的研究进展,为藏药在糖脂代谢性疾病领域的深入研究开发与利用提供参考及研究思路。方法本文通过查阅《晶珠本草》《中华本草之藏药卷》等藏医药书籍及近5年来的藏医药文献,归纳整理分析了治疗糖脂代谢性疾病的藏药研究进展和目前存在的不足。结果从古书籍及文献中查阅到61种具有糖脂代谢性疾病药理活性的单味藏药材和13种常用藏药复方。其中诃子、冬虫夏草等特色药材使用频繁,但多数特色药材未充分开发,缺乏临床证据,作用机制也不完善。结论藏药开发进展慢,缺乏现代文献和临床数据,藏文生涩难懂和药物基源不确定等问题共同导致了藏药的可询证依据较少。表明藏民族医药仍具有较大发展空间,需加大藏药在现代医学体系中的广泛应用和进一步开发。Objective To summarize the research progress of Tibetan medicines in treating glycolipid metabolic diseases,and to provide reference and research ideas for the in-depth research,development and utilization of Tibetan medicines in the field of glycolipid metabolic diseases.Methods This paper summarized and analyzed the research progress and current deficiencies of Tibetan medicines in the treatment of glycolipid metabolic diseases by reviewing the books on Tibetan medicines such as“Jingzhu Materia Medica”and“Chinese Materia Medica Volume of Tibetan Medicines”,as well as the literature on Tibetan medicines in the last 5 years.Results Sixty-one single-flavored Tibetan medicinal herbs with pharmacological activities for glycolipid metabolic diseases and 13 commonly used Tibetan medicinal compound formulas were reviewed from the above ancient books and literatures.Among them,characteristic herbs such as chebulin and Cordyceps sinensis were frequently used,but most of the characteristic herbs were underdeveloped,the lacke of clinical evidence,and had imperfect mechanisms of action.Conclusion The slow progress in the development of Tibetan medicines,the lack of modern literature and clinical data,the difficulty in understanding the Tibetan language and the uncertainty of the drug’s basal source together lead to a less inquiring evidence base for Tibetan medicines.This suggests that there is still much room for the development of Tibetan medicine,and that it is necessary to increase the wide application and further development of Tibetan medicine in the modern medical system.

关 键 词：藏药 糖尿病 高脂血症 非酒精性脂肪性肝病 

分 类 号：R977[医药卫生—药品]